Yes, selecting a Japanese Designated Marketing Authorization Holder (DMAH) involves specific guidelines. Companies must ensure the DMAH is a registered entity in Japan, possesses relevant pharmaceutical expertise, complies with local regulations, and maintains effective communication with Japanese authorities. Additionally, the DMAH should have a robust quality assurance system and reliable distribution network.